Searched for
MANKIND PHARMA STOCK PRICE TARGET
Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...
- Nifty headed to 24,500 next week, says Dharmesh Shah; these 2 stocks are top buys right nowIndian equity markets are poised for further gains, with Nifty eyeing 24,500, according to ICICI Direct's Dharmesh Shah. He highlights fall...
- Missed the FII U-turn? 6 stocks turned multibagger after foreign investors corrected their mistakeForeign institutional investors (FIIs) reversed their selling trend in six select Indian stocks, turning them into multibaggers. Bajaj Cons...
- Hot Stocks: 2 stocks that may give returns between 16-19%Leading brokerages CLSA and Morgan Stanley have initiated coverage on Vedanta Aluminium and Adani Enterprises, respectively, signaling sign...
- Stock Radar: Torrent Power stock showing signs of bottoming out after falling 20% from April 2026 highsTorrent Power shares are showing signs of a comeback after a significant dip, with bulls attempting to regain control. Experts suggest a bu...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- Nomura cuts target price of this AI, data centre beneficiary company. Here’s whyNomura remains positive on Anant Raj despite trimming earnings estimates and lowering its target price due to slower cloud ramp-up and proj...
- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Should investors buy the dip in Vedanta shares after 9% slide? Analysts weigh inVedanta shares fell on Tuesday after promoter entity Twin Star Holdings reportedly sold around 7.3 crore shares (1.7% stake) worth ₹2,149 c...
- India's defence export boom could hit ₹65,000 crore by 2030; pvt sector startups the real play: Sunil SubramaniamIndia's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...
- Stock Radar: Trent broke out from an inverted head & shoulder pattern; time to buy?Trent Ltd stock has broken out of a bullish reversal pattern. Experts recommend buying the stock for a target of Rs 3,500 in the next one t...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 millionZydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
Load More
